|
1
|
Wang Y, Yang H, Liu H, Huang J and Song X:
Effect of staurosporine on the mobility and invasiveness of lung
adenocarcinoma A549 cells: an in vitro study. BMC Cancer.
9:1742009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arora P, Ricks TK and Trejo J:
Protease-activated receptor signalling, endocytic sorting and
dysregulation in cancer. J Cell Sci. 120:921–928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rasmussen UB, Vouret-Craviari V, Jallat S,
Schlesinger Y, Pagès G, Pavirani A, Lecocq JP, Pouysségur J and Van
Obberghen-Schilling E: cDNA cloning and expression of a hamster
alpha-thrombin receptor coupled to Ca2+ mobilization.
FEBS Lett. 288:123–128. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vu TK, Hung DT, Wheaton VI and Coughlin
SR: Molecular cloning of a functional thrombin receptor reveals a
novel proteolytic mechanism of receptor activation. Cell.
64:1057–1068. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Villares GJ, Zigler M, Wang H, et al:
Targeting melanoma growth and metastasis with systemic delivery of
liposome-incorporated protease-activated receptor-1 small
interfering RNA. Cancer Res. 68:9078–9086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tellez C and Bar-Eli M: Role and
regulation of the thrombin receptor (PAR-1) in human melanoma.
Oncogene. 22:3130–3137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chay CH, Cooper CR, Gendernalik JD,
Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH and Pienta
KJ: A functional thrombin receptor (PAR1) is expressed on
bone-derived prostate cancer cell lines. Urology. 60:760–765. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Even-Ram S, Uziely B, Cohen P,
Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and
Bar-Shavit R: Thrombin receptor overexpression in malignant and
physiological invasion processes. Nat Med. 4:909–914. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Darmoul D, Gratio V, Devaud H, Lehy T and
Laburthe M: Aberrant expression and activation of the thrombin
receptor protease-activated receptor-1 induces cell proliferation
and motility in human colon cancer cells. Am J Pathol.
162:1503–1513. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan
L and Li Q: Upregulation of matrix metalloproteinase-1 and
proteinase-activated receptor-1 promotes the progression of human
gliomas. Pathol Res Pract. 207:24–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hernández NA, Correa E, Avila EP, Vela TA
and Pérez VM: PAR1 is selectively over expressed in high grade
breast cancer patients: a cohort study. J Transl Med.
7:472009.PubMed/NCBI
|
|
12
|
Du X, Wang S, Lu J, et al: Correlation
between MMP1-PAR1 axis and clinical outcome of primary gallbladder
carcinoma. Jpn J Clin Oncol. 41:1086–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bar-Shavit R, Turm H, Salah Z, Maoz M,
Cohen I, Weiss E, Uziely B and Grisaru-Granovsky S: PAR1 plays a
role in epithelial malignancies: transcriptional regulation and
novel signaling pathway. IUBMB Life. 63:397–402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tantivejkul K, Loberg RD, Mawocha SC, Day
LL, John LS, Pienta BA, Rubin MA and Pienta KJ: PAR1-mediated
NFkappaB activation promotes survival of prostate cancer cells
through a Bcl-xL-dependent mechanism. J Cell Biochem. 96:641–652.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimizu S, Gabazza EC, Hayashi T, Ido M,
Adachi Y and Suzuki K: Thrombin stimulates the expression of PDGF
in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol.
279:L503–L510. 2000.PubMed/NCBI
|
|
16
|
Huang YQ, Li JJ, Hu L, Lee M and Karpatkin
S: Thrombin induces increased expression and secretion of VEGF from
human FS4 fibroblasts, DU145 prostate cells and CHRF
megakaryocytes. Thromb Haemost. 86:1094–1098. 2001.PubMed/NCBI
|
|
17
|
Boire A, Covic L, Agarwal A, Jacques S,
Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1
receptor that promotes invasion and tumorigenesis of breast cancer
cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Poola I, DeWitty RL, Marshalleck JJ,
Bhatnagar R, Abraham J and Leffall LD: Identification of MMP-1 as a
putative breast cancer predictive marker by global gene expression
analysis. Nat Med. 11:481–483. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Murray GI, Duncan ME, O’Neil P, McKay JA,
Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is
associated with poor prognosis in oesophageal cancer. J Pathol.
185:256–261. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Migita T, Sato E, Saito K, Mizoi T, Shiiba
K, Matsuno S, Nagura H and Ohtani H: Differing expression of MMPs-1
and -9 and urokinase receptor between diffuse- and intestinal-type
gastric carcinoma. Int J Cancer. 84:74–79. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang E, Boire A, Agarwal A, Nguyen N,
O’Callaghan K, Tu P, Kuliopulos A and Covic L: Blockade of PAR1
signaling with cell-penetrating pepducins inhibits Akt survival
pathways in breast cancer cells and suppresses tumor survival and
metastasis. Cancer Res. 69:6223–6231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gartel AL and Kandel ES: RNA interference
in cancer. Biomol Eng. 23:17–34. 2006. View Article : Google Scholar
|
|
23
|
Kim DH and Rossi JJ: Overview of gene
silencing by RNA interference. Curr Protoc Nucleic Acid Chem.
Beaucage SL: 16(Unit 16.1)Wiley; New York, NY: 2009, View Article : Google Scholar
|
|
24
|
Takeshita F and Ochiya T: Therapeutic
potential of RNA interference against cancer. Cancer Sci.
97:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu
H, Liu H and Xiao H: In vitro and in vivo inhibition of MRP gene
expression and reversal of multidrug resistance by siRNA. Basic
Clin Pharmacol Toxicol. 108:177–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiao H, Wu Z, Shen H, Luo AL, Yang YF, Li
XB and Zhu DY: In vivo reversal of P-glycoprotein-mediated
multidrug resistance by efficient delivery of stealth RNAi. Basic
Clin Pharmacol Toxicol. 103:342–348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Perrimon N, Ni JQ and Perkins L: In vivo
RNAi: today and tomorrow. Cold Spring Harb Perspect Biol.
2:a0036402010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seyhan AA: RNAi: a potential new class of
therapeutic for human genetic disease. Hum Genet. 130:583–605.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heller LC, Ugen K and Heller R:
Electroporation for targeted gene transfer. Expert Opin Drug Deliv.
2:255–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li S: Electroporation gene therapy: new
developments in vivo and in vitro. Curr Gene Ther. 4:309–316. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wells DJ: Gene therapy progress and
prospects: electroporation and other physical methods. Gene Ther.
11:1363–1369. 2004. View Article : Google Scholar : PubMed/NCBI
|
